Flares of Systemic Autoimmune Rheumatic Disease Following Coronavirus Disease 2019 Vaccination: A Narrative Review
- PMID: 39550108
- PMCID: PMC11786245
- DOI: 10.1016/j.rdc.2024.08.005
Flares of Systemic Autoimmune Rheumatic Disease Following Coronavirus Disease 2019 Vaccination: A Narrative Review
Abstract
This narrative review summarizes current evidence on the risk of systemic autoimmune rheumatic disease (SARD) flare following coronavirus disease 2019 vaccination. The authors detail key studies in the literature employing diverse methodologies, including cross-sectional surveys, prospective and retrospective cohorts, case-crossover designs, self-controlled case series, and systematic reviews. Data are reassuring, suggesting that vaccination is unlikely to increase the risk of flares across a range of SARD. When postvaccination flares do occur, individuals with high disease activity and frequent flares at baseline may be at higher risk. Rheumatologists may consider discussing these findings with patients during collaborative conversations about risks and benefits of vaccination.
Keywords: Coronavirus disease 2019 vaccination; Federal Drug Agency; Post-vaccination flare; Rheumatologists; Systemic autoimmune rheumatic disease; Systemic autoimmune rheumatic disease flare.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure G. Braverman and M. Nong have no disclosures. M. Barbhaiya is supported by the Rheumatology Research Foundation, United States Investigator Award. L.A. Mandl receives research support from Regeneron Pharmaceuticals, United States and payments from UpToDate, unrelated to this work. L.A. Mandl works as an associate editor for Annals of Internal Medicine.
Similar articles
-
The Flare of Rheumatic Disease After SARS-CoV-2 Vaccination: A Review.Front Immunol. 2022 Jul 4;13:919979. doi: 10.3389/fimmu.2022.919979. eCollection 2022. Front Immunol. 2022. PMID: 35860285 Free PMC article. Review.
-
Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines.Ann Rheum Dis. 2022 Mar;81(3):443-445. doi: 10.1136/annrheumdis-2021-221736. Epub 2021 Nov 25. Ann Rheum Dis. 2022. PMID: 34824048 Free PMC article. No abstract available.
-
Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination.Arthritis Rheumatol. 2022 Jan;74(1):28-32. doi: 10.1002/art.41924. Epub 2021 Dec 3. Arthritis Rheumatol. 2022. PMID: 34346185 Free PMC article.
-
Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey.Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI143-SI150. doi: 10.1093/rheumatology/keac249. Rheumatology (Oxford). 2022. PMID: 35460240 Free PMC article.
-
Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases.Curr Opin Pharmacol. 2022 Aug;65:102243. doi: 10.1016/j.coph.2022.102243. Epub 2022 May 2. Curr Opin Pharmacol. 2022. PMID: 35636384 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
